BreastCancer_ESMO

Equivalence of trastuzumab biosimilar, MYL-1401O, to Herceptin has been demonstrated when given in combination with a taxane as first-line therapy for metastatic breast cancer, as measured by ORR, in the phase III HERITAGE study.

ORR of active agents in locally advanced or metastatic breast cancer progressively decline with each successive therapy line used, according to results of the Spanish CASCADE study.

Adding the CDK4/6 (cyclin-dependent kinase 4/6) inhibitor, ribociclib (formerly LEE011), to letrozole in postmenopausal women with hormone receptor-positive advanced breast cancer increased progression-free survival (PFS) compared to letrozole alone, an interim analysis of the MONALEESA2 (Mammary ONcology Assessment of LEE011's Efficacy and SAfety-2) trial has shown.

Fulvestrant demonstrated superior efficacy over anastrozole for postmenopausal women with hormone-receptor positive (HR+) ABC, this year’s European Society for Medical Oncology Congress was told. Dr Matthew Finn, Director of the Lester and Sue Smith Breast Center, Baylor College of Medicine, US, revealed that the results were more impressive in patients with non-visceral disease.

Recent analytical data were presented at this year’s European Society for Medical Oncology Congress, providing an insight into which ABC patients benefit the most from CDK 4/6 inhibitors. The results showed that ER+ patients were more responsive to the treatment, explained Dr Richard Finn, Associate Professor of Haematology and Oncology at the Geffen School of Medicine, UCLA and the Jonsson Comprehensive Cancer Center, US.